Vis enkel innførsel

dc.contributor.authorAasen, Synnøve Nymarken_US
dc.contributor.authorPospíšilová, Anetaen_US
dc.contributor.authorEichler, Tilo Wolfen_US
dc.contributor.authorPánek, Jiříen_US
dc.contributor.authorHrubý, Martinen_US
dc.contributor.authorŠtěpánek, Petren_US
dc.contributor.authorSpriet, Endyen_US
dc.contributor.authorJirák, Danielen_US
dc.contributor.authorSkaftnesmo, Kai Oveen_US
dc.contributor.authorThorsen, Fritsen_US
dc.date.accessioned2016-01-11T09:17:37Z
dc.date.available2016-01-11T09:17:37Z
dc.date.issued2015-09-08
dc.PublishedInternational Journal of Molecular Sciences 2015, 16(9):21658-21680eng
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/1956/10907
dc.description.abstractTo facilitate efficient drug delivery to tumor tissue, several nanomaterials have been designed, with combined diagnostic and therapeutic properties. In this work, we carried out fundamental in vitro and in vivo experiments to assess the labeling efficacy of our novel theranostic nanoprobe, consisting of glycogen conjugated with a red fluorescent probe and gadolinium. Microscopy and resazurin viability assays were used to study cell labeling and cell viability in human metastatic melanoma cell lines. Fluorescence lifetime correlation spectroscopy (FLCS) was done to investigate nanoprobe stability. Magnetic resonance imaging (MRI) was performed to study T1 relaxivity in vitro, and contrast enhancement in a subcutaneous in vivo tumor model. Efficient cell labeling was demonstrated, while cell viability, cell migration, and cell growth was not affected. FLCS showed that the nanoprobe did not degrade in blood plasma. MRI demonstrated that down to 750 cells/μL of labeled cells in agar phantoms could be detected. In vivo MRI showed that contrast enhancement in tumors was comparable between Omniscan contrast agent and the nanoprobe. In conclusion, we demonstrate for the first time that a non-toxic glycogen-based nanoprobe may effectively visualize tumor cells and tissue, and, in future experiments, we will investigate its therapeutic potential by conjugating therapeutic compounds to the nanoprobe.en_US
dc.language.isoengeng
dc.publisherMDPIeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/eng
dc.subjectmelanoma brain metastasiseng
dc.subjectnanoprobeeng
dc.subjecttheranosticseng
dc.subjectMagnetic resonance imagingeng
dc.subjectfluorescence microscopyeng
dc.subjecthigh throughput microscopyeng
dc.subjectfluorescence lifetime correlation spectroscopyeng
dc.subjectzeta potentialeng
dc.titleA novel nanoprobe for multimodal imaging is effectively incorporated into human melanoma metastatic cell linesen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-12-22T10:36:34Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2015 The Authors
dc.identifier.doihttps://doi.org/10.3390/ijms160921658
dc.identifier.cristin1282250


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY